Which ablation device works best for irregular heartbeat? large trial aims to find out
NCT ID NCT07456540
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will compare different pulse field ablation systems used to treat atrial fibrillation (AF), a common heart rhythm problem. Over 1,100 patients will receive one of the standard treatments depending on the time period they are treated. Researchers will track whether AF returns within 12 months and check for complications within 30 days. The goal is to find out which system is safest and most effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pulse field ablation systems (devices used during catheter ablation)
What this could lead to
If successful, this could identify which ablation system works best to prevent atrial fibrillation from returning, improving treatment choices.
What could go wrong
This is an early-stage comparison study, not a test of a new cure. Results may show no clear winner, and individual outcomes vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rigshospitalet
Copenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••